Codexis, Inc.
Codexis discovers, develops, and sells enzymes and proteins through two segments: Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services, including screening and protein engineering. The company also has a technology platform called CodeEvolver for developing biocatalysts. Codexis collaborates with Nestlé Health Science on CDX-7108 for exocrine pancreatic insufficiency treatment. Products are sold to pharmaceutical manufacturers through direct sales in the US and Europe.
Overview
Strengths
- Improving fundamentals over the last year: return on assets up 14.1 points, gross margin up 14.2 points and asset turnover up 19.6%.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 12.6% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 11.2% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
Key Financial Data